

# Infectious Pathogen Catalogue

<p><b>HPV28 Genotyping Panel</b></p> <p><b>High Risk Types:</b> 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 69, 73, 82</p> <p><b>Low Risk Types:</b> 6, 11, 40, 42, 43, 44, 54, 61, 70</p> <p><b>TAT: 24Hrs</b></p>	<p><b>NTM/MTB Panel</b></p> <ul style="list-style-type: none"> <li>• Mycobacteria Species</li> <li>• M. tuberculosis</li> </ul> <p><b>TAT: 3-5 Days</b></p>	<p><b>MTB/MDR Panel</b></p> <ul style="list-style-type: none"> <li>• Mycobacterium tuberculosis</li> <li>• Isoniazid Resistant M. tuberculosis</li> <li>• Rifampicin Resistant M. tuberculosis</li> </ul> <p><b>TAT: 3-5 Days</b></p>	<p><b>H. pylori &amp; Resistance (Clari) Panel</b></p> <ul style="list-style-type: none"> <li>• Helicobacter pylori (HP)</li> <li>• Clarithromycin resistance (A2143G, A2142G &amp; A2142C in the 23S rRNA gene)</li> </ul> <p><b>TAT: 3-5 Days</b></p>
<p><b>Vaginitis Screening Panel</b></p> <ul style="list-style-type: none"> <li>• Atopobium vaginae (AV)</li> <li>• Candida albicans (CA)</li> <li>• Candida others (CO)</li> <li>• Gardnerella vaginalis (GV)</li> <li>• Lactobacillus spp. (Lacto)</li> <li>• Mobiluncus spp. (Mob)</li> <li>• Trichomonas vaginalis (TV)</li> </ul> <p><b>TAT: 3-5 Days</b></p>	<p><b>Ulcer Pathogen Panel</b></p> <ul style="list-style-type: none"> <li>• Herpes simplex virus type 1 (HSV-1),</li> <li>• Herpes simplex virus type 2 (HSV-2),</li> <li>• Haemophilus ducreyi (HD),</li> <li>• Cytomegalovirus (CMV),</li> <li>• Lymphogranuloma venereum (LGV)</li> <li>• Treponema pallidum (TP)</li> <li>• Varicella-zoster virus (VZV)</li> </ul> <p><b>TAT: 3-5 Days</b></p>	<p><b>STI Essential Panel</b></p> <ul style="list-style-type: none"> <li>• Chlamydia trachomatis (CT)</li> <li>• Neisseria gonorrhoeae (NG)</li> <li>• Mycoplasma genitalium (MG)</li> <li>• Mycoplasma hominis (MH)</li> <li>• Ureaplasma urealyticum (UU)</li> <li>• Ureaplasma parvum (UP)</li> <li>• Trichomonas vaginalis (TV)</li> </ul> <p><b>TAT: 3-5 Days</b></p>	<p><b>Celiac Disease Panel</b></p> <ul style="list-style-type: none"> <li>• HLA – DQ2 (Heterodimer)</li> <li>• HLA – DQ8 (Heterodimer)</li> <li>• HLA – DR4 (Allele Haplotype)</li> </ul> <p><b>TAT: 3-5 Days</b></p>
<p><b>Respiratory Virus Panel</b></p> <ul style="list-style-type: none"> <li>• SARS-CoV-2 (S, N, RdRP Genes)</li> <li>• Influenza A virus (Flu A)</li> <li>• Influenza B virus (Flu B)</li> <li>• Human respiratory syncytial virus (RSV)</li> </ul> <p><b>TAT: 3-5 Days</b></p>	<p><b>Fungal Screening Panel</b></p> <ul style="list-style-type: none"> <li>• C. albicans, C. Parapsilosis, S. brevicaulis</li> <li>• T. rubrum / T. soudanense,</li> <li>• T. interdigitale / T. mentagrophytes</li> <li>• T. violaceum, T. tonsurans, T. mentagrophytes</li> <li>• T. schoenleinii / T. quinckeanum</li> <li>• T. benhamiae, T. verrucosum</li> <li>• M. canis, M. audouinii</li> <li>• E. floccosum, N. gypsea</li> <li>• Generic dermatophyte DNA</li> </ul> <p><b>TAT: 3-5 Days</b></p>	<p><b>Gastrointestinal Pathogen Panel</b></p> <ul style="list-style-type: none"> <li>• Shigella spp./EIEC</li> <li>• Campylobacter spp.</li> <li>• Yersinia enterocolitica</li> <li>• Vibrio spp.</li> <li>• Clostridium difficile toxin B</li> <li>• Aeromonas spp.</li> <li>• Salmonella spp.</li> <li>• Shiga toxin</li> <li>• Enteropathogenic E. coli (EPEC)</li> </ul> <p><b>TAT: 3-5 Days</b></p>	<ul style="list-style-type: none"> <li>• Enterotoxigenic E. coli (ETEC)</li> <li>• Enteroaggregative E. coli (EAEC)</li> <li>• E. coli O157</li> <li>• Hypervirulent Clostridium difficile</li> <li>• Giardia lamblia (GL)</li> <li>• Entamoeba histolytica (EH)</li> <li>• Cryptosporidium spp. (CR)</li> <li>• Blastocystis hominis (BH)</li> <li>• Dientamoeba fragilis (DF)</li> </ul>

# Oncology Catalogue



<p><b>BRAF Mutation Panel</b></p> <p>Mutations Detected:</p> <ul style="list-style-type: none"> <li>• V600E/V600E2/ V600K</li> <li>• V600D/V600D2</li> <li>• V600A/V600R</li> </ul> <p><b>TAT: 3-5 Days</b></p>	<p><b>KRAS/NRAS Mutation Panel</b></p> <p>Mutations Detected:</p> <ul style="list-style-type: none"> <li>• 9 KRAS mutations (exons 2, 3 and 4)</li> <li>• 13 NRAS mutations (exons 2, 3 and 4)</li> </ul> <p><b>TAT: 3-5 Days</b></p>	<p><b>Microsatellite Instability Panel</b></p> <p>MSI Markers Screened:</p> <ul style="list-style-type: none"> <li>• EIF4E3</li> <li>• PPP1CC</li> <li>• PRR5-ARHGAP8</li> <li>• TAOK3</li> <li>• IFT140</li> <li>• UBAC2</li> <li>• ACVR2A</li> <li>• RBM14-RBM4</li> </ul> <p><b>TAT: 3-5 Days</b></p>	<p><b>Somatic Mutations NGS Assay</b></p> <p>Covered genes:</p> <p>ALK*, APC, BRAF, EGFR, ERBB2, KRAS, MET, NRAS, PIK3CA, RET*, ROS1*, SMAD4, TP53</p> <ul style="list-style-type: none"> <li>• Variants: SNVs, InDels, Fusions*</li> <li>• Focused analysis of somatic variants includes SNVs and InDels in 10 key cancer associated genes as well as gene fusion detection in 3 cancer driver genes caused by structural variations. Some of the diseases covered by this panel are non-small cell lung cancer, colorectal cancer, melanoma, thyroid cancer, etc</li> </ul> <p><b>TAT: 10-15 Days</b></p>	<p><b>Hereditary Cancer NGS Assay</b></p> <p>Covered genes:</p> <p>APC, ATM, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PRSS1, PTEN, RAD50, RAD51C, RAD51D, SLX4, SMAD4, STK11, TP53, VHL.</p> <ul style="list-style-type: none"> <li>• Variants: SNVs, InDels, CNVs, MSI*</li> <li>• variant detection of any coding mutation in 31 selected genes associated with an increased risk of hereditary cancer such as hereditary breast and ovarian cancer, Lynch</li> <li>• Syndrome, Li-Fraumeni Syndrome, Cowden Syndrome, etc</li> </ul> <p><b>TAT: 10-15 Days</b></p>
---	---	--	---	--